Acquisitions - Additional Information (Detail) - USD ($)					1 Months Ended				12 Months Ended
	Dec. 03, 2021	May 17, 2021	Mar. 10, 2021	Nov. 06, 2020	Nov. 30, 2021	Oct. 31, 2021	Jul. 31, 2021	Feb. 28, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 17, 2021
Business Combinations [Line Items]
Long-term notes receivable—related parties								$ 100,000	$ 3,835,000	$ 1,060,000
Research and Development in Process									$ 15,480,000	$ 12,020,000
Equity Method Investment, Ownership Percentage									80.00%	80.00%
Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, clinical milestones payment amount							$ 700,000
Recognify Life Sciences, Inc [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired				$ 2,000,000.0
Estimated fair value of contingent consideration				$ 18,000,000.0
Number of days of voting and other rights of expiration date				10 days
Gain or loss in connection with Business Combination									$ 500,000
Business Combination, consideration paid									2,000,000.0
Business Combination, identifiable assets acquired									13,800,000
Business Combination, fair value of the noncontrolling interest issued									12,300,000
Research and Development Expense									11,900,000
PsyProtix Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired								100,000
Estimated fair value of contingent consideration								$ 4,900,000
Number of days of voting and other rights of expiration date								10 days
Company's capital contribution threshold limit								$ 5,000,000.0
Loan received								$ 100,000
Interest rate								5.00%
Aggregate principal amount								$ 100,000
Gain or loss in connection with Business Combination
Business Combination, consideration paid									100,000
Business Combination, identifiable assets acquired									100,000
Business Combination, clinical milestones payment amount						$ 500,000
PsyProtix Purchase Agreement [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, Preferred stock shares						$ 500,000
PsyProtix Purchase Agreement [Member] | PsyProtix, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								75.00%
PsyProtix Purchase Agreement [Member] | Chymia, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								25.00%
Psyber Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired								$ 200,000
Estimated fair value of contingent consideration								$ 1,800,000
Number of days of voting and other rights of expiration date								10 days
Company's capital contribution threshold limit								$ 2,000,000.0
Business Combination, consideration paid									200,000
Business Combination, identifiable assets acquired									200,000
Psyber Purchase Agreement [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, Preferred stock shares							$ 2,437,500
Psyber Purchase Agreement [Member] | Psyber, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								75.00%
Psyber Purchase Agreement [Member] | Psyber, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								25.00%
InnarisBio Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired								$ 1,100,000
Estimated fair value of contingent consideration								$ 3,900,000
Number of days of voting and other rights of expiration date								10 days
Business Combination, consideration paid									1,100,000
Business Combination, identifiable assets acquired									2,000,000.0
Business Combination, fair value of the noncontrolling interest issued									900,000
Purchase consideration for the noncontrolling interest and recognized as a liability									100,000
Business Combination, clinical milestones payment amount					$ 1,200,000
Research and Development in Process									1,000,000.0
InnarisBio Purchase Agreement [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, Preferred stock shares					$ 1,238,000
InnarisBio Purchase Agreement [Member] | InnarisBio, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								82.00%
InnarisBio Purchase Agreement [Member] | UniQuest, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests								18.00%
Neuronasal, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests		56.50%
Gain or loss in connection with Business Combination									3,500,000
Business Combination, consideration paid									1,000,000.0
Business Combination, identifiable assets acquired		$ 8,300,000							3,000,000.0
Research and Development in Process									$ 8,000,000.0
Business Acquisition, Equity Interest Issued or Issuable, Value		800,000
Neuronasal, Inc. [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares		$ 1,000,000.0	$ 800,000
Neuronasal, Inc. [Member] | Common Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares			$ 300,000
TryptageniX, Inc [Member]
Business Combinations [Line Items]
Estimated fair value of contingent consideration	$ 900,000
Business Combination, consideration paid	1,000,000.0
Business Combination, identifiable assets acquired	6,500,000
Business Combination, fair value of the noncontrolling interest issued	3,900,000
Equity Method Investment, Ownership Percentage											65.00%
Fair value of liability for seller financing	800,000
Business Combination, IPR&D asset	6,500,000
Exclusivity fee, Additional payment	1,000,000.0
Exclusivity fee, First Installment	2,000,000.0
Exclusivity fee, Remaining installment	$ 1,000,000.0
TryptageniX, Inc [Member] | Common Class A [Member]
Business Combinations [Line Items]
Held in escrow											$ 2,000,000.0
TryptageniX, Inc [Member] | CBT holding [Member]
Business Combinations [Line Items]
Equity Method Investment, Ownership Percentage											35.00%
Recognify Life Sciences, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests				51.90%